A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients
NCT ID: NCT00002408
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
300 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Crofelemer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV infection meeting CDC criteria for AIDS.
* History of diarrhea for greater than or equal to 14 days prior to screening period (Day 1).
Required:
\- On stable medical regimen.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shaman Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hill Top Research Ltd
Scottsdale, Arizona, United States
Phoenix Living Ctr
Scottsdale, Arizona, United States
UCLA Care Ctr
Los Angeles, California, United States
AIDS Research Ctr / Dept of Veterans Affairs
Palo Alto, California, United States
San Francisco Gen Hosp
San Francisco, California, United States
Lynn House Hospice
West Hollywood, California, United States
AIDS Research Alliance
West Hollywood, California, United States
Howard Univ
Washington D.C., District of Columbia, United States
GCRC
Washington D.C., District of Columbia, United States
Community CRI of South Florida
Coral Gables, Florida, United States
Central Florida Research Initiative
Maitland, Florida, United States
Deering Hosp
Miami, Florida, United States
Rosemont Health Care Ctr
Orlando, Florida, United States
Ctr for Quality Care
Tampa, Florida, United States
Mem Hosp of Tampa
Tampa, Florida, United States
Phillip Branchman
Atlanta, Georgia, United States
Insite Clinical Trials
Decatur, Georgia, United States
Oak Park Hosp
Oak Park, Illinois, United States
Indiana Univ Med Ctr
Indianapolis, Indiana, United States
New Orleans Pharmaceutical Research
Kenner, Louisiana, United States
Johns Hopkins Hosp
Baltimore, Maryland, United States
New England Med Ctr
Boston, Massachusetts, United States
Wayne State Univ
Detroit, Michigan, United States
Hennepin County Med Ctr
Minneapolis, Minnesota, United States
Regions Hosp
Saint Paul, Minnesota, United States
Washington Univ School of Medicine
St Louis, Missouri, United States
Brookdale Univ Hosp and Med Ctr
Brooklyn, New York, United States
Saint Vincents Hosp
New York, New York, United States
Wake Med CRI
Raleigh, North Carolina, United States
Joseph Gathe
Houston, Texas, United States
GCRC - VA Hosp
San Antonio, Texas, United States
South Texas Veterans Health Care System
San Antonio, Texas, United States
Bailey Boushay House
Seattle, Washington, United States
Rosehedge House
Seattle, Washington, United States
Hosp Regional de Ponce
Ponce, , Puerto Rico
Clinical Research Puerto Rico Inc
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
37,554-210
Identifier Type: -
Identifier Source: secondary_id
293A
Identifier Type: -
Identifier Source: org_study_id